News

IonSense’s DART-MS Technology Selected for New Drug Screening Program

January 28, 2022

IonSense’s DART-MS technology offers rapid drug analysis without the need for sample preparation.

Texcell North America Builds New Laboratory Facility

January 28, 2022

Texcell North America’s new lab facility in Frederick, Md., will expand the CRO’s capabilities in R&D cell culture, viral clearance studies, and viral safety testing.

Refeyn Announces SamuxMP for AAV Characterization

January 28, 2022

Refeyn’s SamuxMP enables routine quantification of empty/full AAV capsid ratios, even in smaller labs, to set a new standard in AAV characterization

Samsung Biologics to Acquire Full Ownership of Samsung Bioepis in $2.3 Billion Deal

January 28, 2022

Samsung Biologics has signed an agreement with Biogen to acquire Biogen’s 50% stake in Samsung Bioepis, a joint venture formed by the two companies, for up to $2.3 billion.

PhoreMost Collaborates with Polaris and NeoCura on Cancer Therapeutics

January 28, 2022

PhoreMost has entered into separate collaboration agreements with Polaris Quantum Biotech and NeoCura Bio-Medical Technology to discover and develop novel cancer therapeutics.

BenchSci Raises $63 Million in Series C Financing Round

January 28, 2022

BenchSci, a specialist in machine learning applications for novel medicine development, has completed a Series C financing round.

Scottish Biotech Secures Millions in Commercialization Investment Funds

January 28, 2022

Scottish biotech engineering company, uFraction8, has successfully secured more than £2.5 million ($3.3 million) in new investment.

NICE Updates Guidance for Lokelma as Treatment for Adults with Hyperkalemia

January 28, 2022

NICE has updated its Technology Appraisal Guidance TA599 for AstraZeneca’s Lokelma.

Catalent Expands its High Potency Micronization Capabilities in both US and UK

January 28, 2022

Catalent has expanded its Malvern, Pennsylvania, USA, and Dartford, UK, facilities to provide advanced containment capabilities for the micronization of highly potent drug compounds.

PharmaLex furthers its clinical and regulatory reach

January 27, 2022

Merger with Phlexglobal expands provider’s technological capabilities.